Despite considerable advancements, the development of effective cancer screening tools based on serum biomarker measurements has thus far failed to achieve a meaningful clinical impact. The incremental progress observed over the course of serum biomarker development suggests that further refinements based on novel approaches may yet result in a breakthrough. The use of urine as an analytical biofluid for biomarker development may represent such an approach. The unique characteristics of urine including a high level of stability, ease of sampling, and an inactive and low-complexity testing matrix offer several potential advantages over the use of serum. A number of recent reports have demonstrated the utility of urine in the identification of novel cancer biomarkers and also the improved performance of biomarkers previously evaluated in serum. In this review, advancements related to the use of urine biomarkers within the settings of ovarian, breast, and pancreatic cancer are presented and discussed. Findings regarding the identification of specific urine biomarkers for each disease are highlighted along with comparative analyses of urine and serum biomarkers as diagnostic tools.
KoomenJ.M., LiD., XiaoL.C.Direct tandem mass spectrometry reveals limitations in protein profiling experiments for plasma biomarker discovery.J Proteome Res2005; 4: 972–81.
2.
TeisnerB., DaveyM.W., GrudzinskasJ.G.Interaction between heparin and plasma proteins analysed by crossed immunoelectrophoresis and affinity chromatography.Clin Chim Acta1983; 127: 413–7.
3.
CoonJ.J., ZürbigP., DaknaM.CE-MS analysis of the human urinary proteome for biomarker discovery and disease diagnostics.Proteomics Clin Appl2008; 2: 964–73.
4.
SchaubS., WilkinsJ., WeilerT., SangsterK., RushD., NickersonP.Urine protein profiling with surface-enhanced laser-desorption/ionization time-of-flight mass spectrometry.Kidney Int2004; 65: 323–32.
5.
DecramerS., Gonzalez de PeredoA., BreuilB.Urine in clinical proteomics.Mol Cell Proteomics2008; 7: 1850–62.
6.
YeB., SkatesS., MokS.C.Proteomic-based discovery and characterization of glycosylated eosinophil-derived neurotoxin and COOH-terminal osteopontin fragments for ovarian cancer in urine.Clin Cancer Res2006; 12: 432–41.
7.
SchifferE., MischakH., NovakJ.High resolution proteome/peptidome analysis of body fluids by capillary electrophoresis coupled with MS.Proteomics2006; 6: 5615–27.
ThongboonkerdV., MalasitP.Renal and urinary proteomics: current applications and challenges.Proteomics2005; 5: 1033–42.
10.
ColeL.A., SchwartzP.E., WangY.X.Urinary gonadotropin fragments (UGF) in cancers of the female reproductive system. I. Sensitivity and specificity, comparison with other markers.Gynecol Oncol1988; 31: 82–90.
11.
PlebaniM., NavagliaF., BassoD.Combined use of urinary UGP and serum CA 125 in the diagnosis of gynecological cancers.Anticancer Res1996; 16: 3833–8.
12.
WalkerR., CrebbinV., SternJ., ScudderS., SchwartzP.Urinary gonadotropin peptide (UGP) as a marker of gynecologic malignancies.Anticancer Res1994; 14: 1703–9.
13.
HellstromI., HeagertyP.J., SwisherE.M.Detection of the HE4 protein in urine as a biomarker for ovarian neoplasms.Cancer Lett2010; 296: 43–8.
14.
BadgwellD., LuZ., ColeL.Urinary mesothelin provides greater sensitivity for early stage ovarian cancer than serum mesothelin, urinary hCG free beta subunit and urinary hCG beta core fragment.Gynecol Oncol2007; 106: 490–7.
15.
AndersonN.S., BermudezY., BadgwellD.Urinary levels of Bcl-2 are elevated in ovarian cancer patients.Gynecol Oncol2009; 112: 60–7.
16.
DrenbergC.D., SaundersB.O., WilbanksG.D.Urinary angiostatin levels are elevated in patients with epithelial ovarian cancer.Gynecol Oncol2010; 117: 117–24.
17.
Abdullah-SoheimiS.S., LimB.K., HashimO.H., ShuibA.S.Patients with ovarian carcinoma excrete different altered levels of urine CD59, kininogen-1 and fragments of inter-alpha-trypsin inhibitor heavy chain H4 and albumin.Proteome Sci2010; 8: 58.
18.
PetriA.L., SimonsenA.H., HogdallE.Comparison of proteomic biomarker panels in urine and serum for ovarian cancer diagnosis.Proteomics Clin Appl2010; 4: 304–14.
19.
PetriA.L., SimonsenA.H., YipT.T.Three new potential ovarian cancer biomarkers detected in human urine with equalizer bead technology.Acta Obstet Gynecol Scand2009; 88: 18–26.
20.
SlupskyC.M., SteedH., WellsT.H.Urine metabolite analysis offers potential early diagnosis of ovarian and breast cancers.Clin Cancer Res2010; 16: 5835–41.
21.
NolenB., VelikokhatnayaL., MarrangoniA.Serum biomarker panels for the discrimination of benign from malignant cases in patients with an adnexal mass.Gynecol Oncol2010; 117: 440–5.
22.
YurkovetskyZ., SkatesS., LomakinA.Development of a multimarker assay for early detection of ovarian cancer.J Clin Oncol2010; 28: 2159–66.
23.
JacobsI.J., MenonU.Progress and challenges in screening for early detection of ovarian cancer.Mol Cell Proteomics2004; 3: 355–66.
24.
MenonU., JacobsI.J.Ovarian cancer screening in the general population: current status.Int J Gynecol Cancer2001; 11(Suppl 1): 3–6.
25.
MacDonaldN.D., RosenthalA.N., JacobsI.J.Screening for ovarian cancer.Ann Acad Med Singapore1998; 27: 676–82.
26.
MooreR.G., BrownA.K., MillerM.C.The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass.Gynecol Oncol2008; 108: 402–8.
27.
MooreR.G., McMeekinD.S., BrownA.K.A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass.Gynecol Oncol2009; 112: 40–6.
28.
MooreR.G., Jabre-RaughleyM., BrownA.K.Comparison of a novel multiple marker assay vs the Risk of Malignancy Index for the prediction of epithelial ovarian cancer in patients with a pelvic mass.Am J Obstet Gynecol2010; 203: 228e1–6.
29.
American Cancer Society Statistics. (Accessed at www.cancer.org.)
30.
CarneyP.A., MigliorettiD.L., YankaskasB.C.Individual and combined effects of age, breast density, and hormone replacement therapy use on the accuracy of screening mammography.Ann Intern Med2003; 138: 168–75.
31.
KopansD.B.Clinical breast examination for detecting breast cancer.JAMA2000; 283: 1688; author reply 1689.
32.
BakerL.H.Breast Cancer Detection Demonstration Project: five-year summary report.CA Cancer J Clin1982; 32: 194–225.
33.
FoxcroftL.M., EvansE.B., JoshuaH.K., HirstC.Breast cancers invisible on mammography.Aust N Z J Surg2000; 70: 162–7.
34.
BartschR., WenzelC., PluschnigU.Prognostic value of monitoring tumour markers CA 15-3 and CEA during fulvestrant treatment.BMC Cancer2006; 6: 81.
35.
GionM., MioneR., BeccioliniA.Relationship between cytosol TPS, TPA and cell proliferation.Int J Biol Markers1994; 9: 109–14.
36.
MolinaR., AgustiC., FilellaX.Study of a new tumor marker, CYFRA 21-1, in malignant and nonmalignant diseases.Tumour Biol1994; 15: 318–25.
37.
FuckarD., DekanicA., StifterS.VEGF expression is associated with negative estrogen receptor status in patients with breast cancer.Int J Surg Pathol2006; 14: 49–55.
38.
LeonardG.D., LowJ.A., BermanA.W., SwainS.M.CA 125 elevation in breast cancer: a case report and review of the literature.Breast J2004; 10: 146–9.
39.
DanforthD.N.Jr., SgagiasM.K.Interleukin-1 alpha and interleukin-6 act additively to inhibit growth of MCF-7 breast cancer cells in vitro.Cancer Res1993; 53: 1538–45.
40.
TaniguchiT., ToiM., InadaK., ImazawaT., YamamotoY., TominagaT.Serum concentrations of hepatocyte growth factor in breast cancer patients.Clin Cancer Res1995; 1: 1031–4.
41.
OhuchiN., MatobaN., TairaY.Levels of circulating tumor-associated glycoprotein (TAG-72) in patients with carcinoma using a novel tumor marker, CA 72-4.Gan To Kagaku Ryoho1988; 15: 2767–72.
42.
YousefG.M., DiamandisE.P.Expanded human tissue kallikrein family–a novel panel of cancer biomarkers.Tumour Biol2002; 23: 185–92.
43.
KimY., KooI., JungB.H., ChungB.C., LeeD.Multivariate classification of urine metabolome profiles for breast cancer diagnosis.BMC Bioinformatics2010; 11(Suppl 2): S4.
44.
NamH., ChungB.C., KimY., LeeK., LeeD.Combining tissue transcriptomics and urine metabolomics for breast cancer biomarker identification.Bioinformatics2009; 25: 3151–7.
45.
FrickenschmidtA., FrohlichH., BullingerD.Metabonomics in cancer diagnosis: mass spectrometry-based profiling of urinary nucleosides from breast cancer patients.Biomarkers2008; 13: 435–49.
46.
SchernhammerE.S., BerrinoF., KroghV.Urinary 6-sulphatoxymelatonin levels and risk of breast cancer in premenopausal women: the ORDET cohort.Cancer Epidemiol Biomarkers Prev2010; 19: 729–37.
47.
SchernhammerE.S., BerrinoF., KroghV.Urinary 6-sulfatoxymelatonin levels and risk of breast cancer in postmenopausal women.J Natl Cancer Inst2008; 100: 898–905.
48.
SchernhammerE.S., HankinsonS.E.Urinary melatonin levels and postmenopausal breast cancer risk in the Nurses' Health Study cohort.Cancer Epidemiol Biomarkers Prev2009; 18: 74–9.
49.
PoriesS.E., ZurakowskiD., RoyR.Urinary metalloproteinases: noninvasive biomarkers for breast cancer risk assessment.Cancer Epidemiol Biomarkers Prev2008; 17: 1034–42.
50.
UmemoriY., OheY., KuribayashiK.Evaluating the utility of N1,N12-diacetylspermine and N1,N8-diacetylspermidine in urine as tumor markers for breast and colorectal cancers.Clin Chim Acta2010; 411: 1894–9.
51.
WardH., ChapelaisG., KuhnleG.G., LubenR., KhawK.T., BinghamS.Breast cancer risk in relation to urinary and serum biomarkers of phytoestrogen exposure in the European Prospective into Cancer-Norfolk cohort study.Breast Cancer Res2008; 10: R32.
GhadirianP., LynchH.T., KrewskiD.Epidemiology of pancreatic cancer: an overview.Cancer Detect Prev2003; 27: 87–93.
54.
LowenfelsA.B., MaisonneuveP.Epidemiologic and etiologic factors of pancreatic cancer.Hematol Oncol Clin North Am2002; 16: 1–16.
55.
MichaudD.S.Epidemiology of pancreatic cancer.Minerva Chir2004; 59: 99–111.
56.
SohnT.A., YeoC.J., CameronJ.L.Resected adenocarcinoma of the pancreas-616 patients: results, outcomes, and prognostic indicators.J Gastrointest Surg2000; 4: 567–79.
57.
GoonetillekeK.S., SiriwardenaA.K.Systematic review of carbohydrate antigen (CA 19-9) as a biochemical marker in the diagnosis of pancreatic cancer.Eur J Surg Oncol2007; 33: 266–70.
58.
ArganiP., Iacobuzio-DonahueC., RyuB.Mesothelin is overexpressed in the vast majority of ductal adenocarcinomas of the pancreas: identification of a new pancreatic cancer marker by serial analysis of gene expression (SAGE).Clin Cancer Res2001; 7: 3862–8.
59.
EskelinenM., HaglundU.Developments in serologic detection of human pancreatic adenocarcinoma.Scand J Gastroenterol1999; 34: 833–44.
60.
HustinxS.R., CaoD., MaitraA.Differentially expressed genes in pancreatic ductal adenocarcinomas identified through serial analysis of gene expression.Cancer Biol Ther2004; 3: 1254–61.
61.
KoopmannJ., RosenzweigC.N., ZhangZ.Serum markers in patients with resectable pancreatic adenocarcinoma: macrophage inhibitory cytokine 1 versus CA19-9.Clin Cancer Res2006; 12: 442–6.
62.
SlesakB., Harlozinska-SzmyrkaA., KnastW., SedlaczekP., van DalenA., EinarssonR.Tissue polypeptide specific antigen (TPS), a marker for differentiation between pancreatic carcinoma and chronic pancreatitis. A comparative study with CA 19-9.Cancer2000; 89: 83–8.
63.
ZhouW., SokollL.J., BruzekD.J.Identifying markers for pancreatic cancer by gene expression analysis.Cancer Epidemiol Biomarkers Prev1998; 7: 109–12.
64.
MoniauxN., ChakrabortyS., YalnizM.Early diagnosis of pancreatic cancer: neutrophil gelatinase-associated lipocalin as a marker of pancreatic intraepithelial neoplasia.Br J Cancer2008; 98: 1540–7.
65.
Carpelan-HolmstromM., LouhimoJ., StenmanU.H., AlfthanH., HaglundC.CEA, CA 19-9 and CA 72-4 improve the diagnostic accuracy in gastrointestinal cancers.Anticancer Res2002; 22: 2311–6.
66.
HayakawaT., NaruseS., KitagawaM.A prospective multicenter trial evaluating diagnostic validity of multivariate analysis and individual serum marker in differential diagnosis of pancreatic cancer from benign pancreatic diseases.Int J Pancreatol1999; 25: 23–9.
67.
FacaV.M., SongK.S., WangH.A mouse to human search for plasma proteome changes associated with pancreatic tumor development.PLoS Med2008; 5: e123.
68.
BrandR.E., NolenB.M., ZehH.J.Serum biomarker panels for the detection of pancreatic cancer.Clin Cancer Res2011; 17: 805–16.
69.
DianxuF., ShengdaoZ., TianquanH.A prospective study of detection of pancreatic carcinoma by combined plasma K-ras mutations and serum CA19–9 analysis.Pancreas2002; 25: 336–41.
70.
WangJ., ChenJ., ChangP.MicroRNAs in plasma of pancreatic ductal adenocarcinoma patients as novel blood-based biomarkers of disease.Cancer Prev Res (Phila)2009; 2: 807–13.
71.
ZhangL., FarrellJ.J., ZhouH.Salivary transcriptomic biomarkers for detection of resectable pancreatic cancer.Gastroenterology; 138: 949–57e1–7.
72.
AllenP.J., QinL.X., TangL., KlimstraD., BrennanM.F., LokshinA.Pancreatic cyst fluid protein expression profiling for discriminating between serous cystadenoma and intraductal papillary mucinous neoplasm.Ann Surg2009; 250: 754–60.
73.
HaabB.B., PorterA., YueT.Glycosylation variants of mucins and CEACAMs as candidate biomarkers for the diagnosis of pancreatic cystic neoplasms.Ann Surg; 251: 937–45.
74.
MotooY., WatanabeH., YamaguchiY.Urinary gonadotropin peptide in patients with cancer of digestive organs.Anticancer Res1996; 16: 2041–8.
75.
WeeksM.E., HariharanD., PetronijevicL.Analysis of the urine proteome in patients with pancreatic ductal adenocarcinoma.Proteomics Clin Appl2008; 2: 1047–57.
76.
SzajdaS.D., SnarskaJ., JankowskaA., PuchalskiZ., ZwierzK.Isoenzymes A and B of N-acetyl-beta-D-hexosaminidase in serum and urine of patients with pancreatic cancer.Hepatogastroenterology2008; 55: 695–8.
YamaguchiK., NakamuraM., ShirahaneK.Urine diacetylspermine as a novel tumour maker for pancreatobiliary carcinomas.Dig Liver Dis2005; 37: 190–4.
79.
RuggieroA., VillaC.H., BanderE.Paradoxical glomerular filtration of carbon nanotubes.Proc Natl Acad Sci U S A2010; 107: 12369–74.
80.
HeavnerD.L., MorganW.T., SearsS.B., RichardsonJ.D., ByrdG.D., OgdenM.W.Effect of creatinine and specific gravity normalization techniques on xenobiotic biomarkers in smokers' spot and 24-h urines.J Pharm Biomed Anal2006; 40: 928–42.
81.
SuwazonoY., ÅkessonA., AlfvénT., JärupL., VahterM.Creatinine versus specific gravity-adjusted urinary cadmium concentrations.Biomarkers2005; 10: 117–26.
82.
AlessioL., BerlinA., Dell'OrtoA., ToffolettoF., GhezziI.Reliability of urinary creatinine as a parameter used to adjust values of urinary biological indicators.Int Arch Occup Environ Health1985; 55: 99–106.
83.
CurtisG., FogelM.Creatinine excretion: diurnal variation and variability of whole and part-day measures. A methodologic issue in psychoendocrine research.Psychosom Med1970; 32: 337–50.
84.
HsuJ., JohansenK.L., HsuC.Y., KaysenG.A., ChertowG.M.Higher serum creatinine concentrations in black patients with chronic kidney disease: beyond nutritional status and body composition.Clin J Am Soc Nephrol2008; 3: 992–7.
85.
JonesC.A., McQuillanG.M., KusekJ.W.Serum creatinine levels in the US population: third National Health and Nutrition Examination Survey.Am J Kidney Dis1998; 32: 992–9.
86.
JatlowP., McKeeS., O'MalleyS.S.Correction of urine cotinine concentrations for creatinine excretion: is it useful?Clin Chem2003; 49: 1932–4.
87.
WaikarS.S., SabbisettiV.S., BonventreJ.V.Normalization of urinary biomarkers to creatinine during changes in glomerular filtration rate.Kidney Int2010; 78: 486–94.
88.
Al-AloulM., JacksonM., BellG., LedsonM., WalshawM.Comparison of methods of assessment of renal function in cystic fibrosis (CF) patients.J Cyst Fibros2007; 6: 41–7.
89.
Al-AloulM., MillerH., AlapatiS., StocktonP.A., LedsonM.J., WalshawM.J.Renal impairment in cystic fibrosis patients due to repeated intravenous aminoglycoside use.Pediatr Pulmonol2005; 39: 15–20.
90.
NeubertA., RemerT.The impact of dietary protein intake on urinary creatinine excretion in a healthy pediatric population.J Pediatr1998; 133: 655–9.
91.
PennerS.B., BernsteinK.N., FineA.Changes in endogenous creatinine clearance in man on a controlled protein diet: Effect of route of administration of a protein load.Clin Invest Med1990; 13: 233–6.
92.
TanK.H.V., MulheranM., KnoxA.J., SmythA.R.Aminoglycoside prescribing and surveillance in cystic fibrosis.Am J Respir Crit Care Med2003; 167: 819–23.
93.
WorsfoldM., DavieM.W.J., HaddawayM.J.Age-related changes in body composition, hydroxyproline, and creatinine excretion in normal women.Calcif Tissue Int1999; 64: 40–4.
